BNTX (US) share price forecast & AI signal — BioNTech SE
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in BNTX
BioNTech SE is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a SELL with low confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $87.51 |
| 2026-11-05 | $85.86 |
| 2026-11-04 | $90.70 |
| 2026-11-03 | $86.92 |
| 2026-11-02 | $87.53 |
| 2026-10-30 | $88.17 |
| 2026-10-29 | $89.13 |
BNTX FAQ
Is BioNTech SE (BNTX) a buy or sell this week?
The ACE Stock Bots machine-learning model rates BNTX a SELL for the week of 2026-10-30 with low confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for BNTX?
Every week the model scores BNTX across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.